Key Takeaways
- ARK Invest acquired approximately 281,000 shares of CRSP valued at roughly $14.82M following a 10% decline
- CRISPR Therapeutics sparked the selloff by announcing a $350M private placement
- The gene-editing company represents ARK’s second-largest position overall, with approximately $500M in total holdings
- ARK reduced stakes in 10x Genomics (TXG) and Teradyne (TER) during portfolio rebalancing
- Both Seeking Alpha Quant ratings and Wall Street consensus assign CRSP a Buy rating
Shares of CRISPR Therapeutics (CRSP) tumbled approximately 10% following news of a $350M private placement. Cathie Wood’s ARK Invest seized the opportunity to add to its position.
According to ARK’s daily trading disclosure dated March 11, 2026, the investment firm acquired roughly 281,000 shares of CRSP distributed across its various ETFs, representing approximately $14.82M in total value.
This purchase extends a pattern established in recent months. During the fourth quarter of 2025, Wood had already expanded ARK’s CRSP holdings by 7.5%, bringing in about 735,000 additional shares. The recent acquisition reinforces that bullish stance.
CRSP has become ARK’s second-most significant position when looking at the firm’s combined ETF portfolio, accounting for a 4.49% allocation and approximately $500M in aggregate exposure. This represents substantial conviction in a company still in its pre-revenue phase.
Private Placement Triggers Selloff
The sharp decline materialized after CRISPR Therapeutics disclosed plans for a $350M private capital raise. Such offerings typically result in shareholder dilution, creating downward pressure on share prices.
The fundraising move wasn’t particularly surprising given the company’s financial profile. Operating without revenue and posting negative margins, CRISPR Therapeutics relies on capital injections to advance its development pipeline.
However, the company maintains robust financial health in other respects — boasting a current ratio of 13.32 and a minimal debt-to-equity ratio of 0.11, indicating strong liquidity paired with negligible leverage.
This solid financial foundation likely contributed to ARK’s confidence in accumulating shares during the pullback.
CRISPR’s Development Pipeline
The company’s initial commercial product, Casgevy, emerged from collaboration with Vertex Pharmaceuticals and addresses sickle-cell disease and transfusion-dependent beta-thalassemia.
Looking ahead, CRISPR Therapeutics maintains active research programs spanning immuno-oncology, cardiovascular applications, and stem cell-based treatments for Type 1 diabetes.
Current market capitalization stands at roughly $5.07 billion based on recent valuations.
Insider transaction patterns show a clear trend — five separate insider sales totaling 163,751 shares occurred over the previous three months, with zero insider purchases recorded during that period.
Portfolio Adjustments Across Holdings
While accumulating CRSP shares, ARK simultaneously reduced exposure elsewhere. The firm divested 78,412 shares of 10x Genomics (TXG) valued at approximately $1.60M and sold 21,505 shares of Teradyne (TER) worth $6.47M.
These transactions appear consistent with standard portfolio rebalancing practices typical of ARK’s active management approach, rather than signaling negative sentiment toward those particular companies.
From an analyst perspective, CRSP maintains Buy ratings from both Seeking Alpha’s Quant algorithm and the Wall Street analyst community. The Quant system particularly highlights strong scores in growth and momentum categories.
A Seeking Alpha analyst highlighted Casgevy’s market entry and the company’s cash position as notable strengths, while acknowledging the inherent uncertainties associated with pre-revenue biotechnology investments.
GuruFocus assigns a GF Value of $16.13 to CRSP, categorizing the shares as significantly overvalued — a perspective that contrasts with the predominantly bullish analyst outlook.
Shares closed approximately 10.17% lower on the session when the offering was announced.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
